請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/42887
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 廖泰慶(Albert Taiching Liao),朱瑞民(Rea-Min Chu) | |
dc.contributor.author | Tien-Fu Chuang | en |
dc.contributor.author | 莊添富 | zh_TW |
dc.date.accessioned | 2021-06-15T01:27:37Z | - |
dc.date.available | 2016-08-22 | |
dc.date.copyright | 2011-08-22 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-08-16 | |
dc.identifier.citation | 1. Richards HG, McNeil PE, Thompson H, Reid SW. An epidemiological analysis of a canine-biopsies database compiled by a diagnostic histopathology service. Prev Vet Med 2001; 51: 125-36.
2. Hayes HM, Tarone RE, Cantor KP, Jessen CR, McCurnin DM, Richardson RC. Case-control study of canine malignant lymphoma: positive association with dog owner's use of 2,4-dichlorophenoxyacetic acid herbicides. J Natl Cancer Inst 1991; 83: 1226-31. 3. Bronson RT. Variation in age at death of dogs of different sexes and breeds. Am J Vet Res 1982; 43: 2057-9. 4. Dobson JM, Samuel S, Milstein H, Rogers K, Wood JL. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J Small Anim Pract 2002; 43: 240-6. 5. Merlo DF, Rossi L, Pellegrino C, et al. Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. J Vet Intern Med 2008; 22: 976-84. 6. Dorn CR, Taylor DO, Frye FL, Hibbard HH. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. I. Methodology and description of cases. J Natl Cancer Inst 1968; 40: 295-305. 7. Dorn CR, Taylor DO, Schneider R, Hibbard HH, Klauber MR. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 1968; 40: 307-18. 8. Vascellari M, Baioni E, Ru G, Carminato A, Mutinelli F. Animal tumour registry of two provinces in northern Italy: incidence of spontaneous tumours in dogs and cats. BMC Vet Res 2009; 5: 39. 9. Bronden LB, Flagstad A, Kristensen AT. Veterinary cancer registries in companion animal cancer: a review. Vet Comp Oncol 2007; 5: 133-44. 10. Priester WA, Mantel N. Occurrence of tumors in domestic animals. Data from 12 United States and Canadian colleges of veterinary medicine. J Natl Cancer Inst 1971; 47: 1333-44. 11. Lee CJ. Retrospective Survey of Canine Neoplasm in the National Taiwan University Veterinary Hospital: 1999-2003. Master's Thesis 2005. 12. Bergman PJ. Canine oral melanoma. Clin Tech Small Anim Pract 2007; 22: 55-60. 13. Todoroff RJ, Brodey RS. Oral and pharyngeal neoplasia in the dog: a retrospective survey of 361 cases. J Am Vet Med Assoc 1979; 175: 567-71. 14. Boria PA, Murry DJ, Bennett PF, et al. Evaluation of cisplatin combined with piroxicam for the treatment of oral malignant melanoma and oral squamous cell carcinoma in dogs. J Am Vet Med Assoc 2004; 224: 388-94. 15. Theon AP, Rodriguez C, Madewell BR. Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation. J Am Vet Med Assoc 1997; 210: 778-84. 16. Egenvall A, Bonnett BN, Ohagen P, Olson P, Hedhammar A, von Euler H. Incidence of and survival after mammary tumors in a population of over 80,000 insured female dogs in Sweden from 1995 to 2002. Prev Vet Med 2005; 69: 109-27. 17. de MSCH, Toledo-Piza E, Amorin R, Barboza A, Tobias KM. Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Can Vet J 2009; 50: 506-10. 18. Schneider R, Dorn CR, Taylor DO. Factors influencing canine mammary cancer development and postsurgical survival. J Natl Cancer Inst 1969; 43: 1249-61. 19. Misdorp W. Progestagens and mammary tumours in dogs and cats. Acta Endocrinol (Copenh) 1991; 125 Suppl 1: 27-31. 20. Novosad CA. Principles of treatment for mammary gland tumors. Clin Tech Small Anim Pract 2003; 18: 107-9. 21. Karayannopoulou M, Kaldrymidou E, Constantinidis TC, Dessiris A. Adjuvant post-operative chemotherapy in bitches with mammary cancer. J Vet Med A Physiol Pathol Clin Med 2001; 48: 85-96. 22. Philibert JC, Snyder PW, Glickman N, Glickman LT, Knapp DW, Waters DJ. Influence of host factors on survival in dogs with malignant mammary gland tumors. J Vet Intern Med 2003; 17: 102-6. 23. Sartin EA, Barnes S, Toivio-Kinnucan M, Wright JC, Wolfe LG. Heterogenic properties of clonal cell lines derived from canine mammary carcinomas and sensitivity to tamoxifen and doxorubicin. Anticancer Res 1993; 13: 229-36. 24. Cappelletti V, Granata G, Miodini P, et al. Modulation of receptor levels in canine breast tumors by administration of tamoxifen and etretinate either alone or in combination. Anticancer Res 1988; 8: 1297-301. 25. Tavares WL, Lavalle GE, Figueiredo MS, et al. Evaluation of adverse effects in tamoxifen exposed healthy female dogs. Acta Vet Scand; 52: 67. 26. Waddle JR, Fine RL, Case BC, et al. Phase I and pharmacokinetic analysis of high-dose tamoxifen and chemotherapy in normal and tumor-bearing dogs. Cancer Chemother Pharmacol 1999; 44: 74-80. 27. Morris JS, Dobson JM, Bostock DE. Use of tamoxifen in the control of canine mammary neoplasia. Vet Rec 1993; 133: 539-42. 28. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol 2003; 21: 2415-32. 29. Haupt K, Roggendorf M, Mann K. The potential of DNA vaccination against tumor-associated antigens for antitumor therapy. Exp Biol Med (Maywood) 2002; 227: 227-37. 30. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7. 31. Tamura Y, Peng P, Liu K, Daou M, Srivastava PK. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 1997; 278: 117-20. 32. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998; 25: 623-35. 33. Houghton AN. Cancer antigens: immune recognition of self and altered self. J Exp Med 1994; 180: 1-4. 34. Sioud M, Hansen MH. Profiling the immune response in patients with breast cancer by phage-displayed cDNA libraries. Eur J Immunol 2001; 31: 716-25. 35. Lin CC, Chou CW, Shiau AL, et al. Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu. Mol Ther 2004; 10: 290-301. 36. Dyall R, Bowne WB, Weber LW, et al. Heteroclitic immunization induces tumor immunity. J Exp Med 1998; 188: 1553-61. 37. Berzofsky JA, Terabe M, Oh S, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004; 113: 1515-25. 38. Srinivasan R, Wolchok JD. Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines. J Transl Med 2004; 2: 12. 39. Choo AY, Choo DK, Kim JJ, Weiner DB. DNA vaccination in immunotherapy of cancer. Cancer Treat Res 2005; 123: 137-56. 40. Lu Y, Wei YQ, Tian L, et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol 2003; 170: 3162-70. 41. Curcio C, Di Carlo E, Clynes R, et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 2003; 111: 1161-70. 42. Gregor PD, Wolchok JD, Turaga V, et al. Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer 2005; 116: 415-21. 43. Kim JJ, Yang JS, Nottingham LK, et al. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen. Oncogene 2001; 20: 4497-506. 44. Weber LW, Bowne WB, Wolchok JD, et al. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 1998; 102: 1258-64. 45. Liu JY, Wei YQ, Yang L, et al. Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 2003; 102: 1815-23. 46. Bergman PJ, Camps-Palau MA, McKnight JA, et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 2006; 24: 4582-5. 47. Hawkins WG, Gold JS, Dyall R, et al. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. Surgery 2000; 128: 273-80. 48. Bergman PJ, McKnight J, Novosad A, et al. Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 2003; 9: 1284-90. 49. Liao JC, Gregor P, Wolchok JD, et al. Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. Cancer Immun 2006; 6: 8. 50. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61 Suppl 2: 1-13. 51. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12. 52. Cohen JA, Weiner DB, More KF, et al. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 1989; 4: 81-8. 53. Weiner DB, Nordberg J, Robinson R, et al. Expression of the neu gene-encoded protein (P185neu) in human non-small cell carcinomas of the lung. Cancer Res 1990; 50: 421-5. 54. Menard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570-8. 55. Santin AD, Bellone S, Roman JJ, McKenney JK, Pecorelli S. Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu. Int J Gynaecol Obstet 2008; 102: 128-31. 56. Le XF, Pruefer F, Bast RC, Jr. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle 2005; 4: 87-95. 57. Hsu WL, Huang HM, Liao JW, Wong ML, Chang SC. Increased survival in dogs with malignant mammary tumours overexpressing HER-2 protein and detection of a silent single nucleotide polymorphism in the canine HER-2 gene. Vet J 2009; 180: 116-23. 58. Kim MS, Kim T, Kong SY, et al. Breast cancer diagnosis using a microfluidic multiplexed immunohistochemistry platform. PLoS One; 5: e10441. 59. Smith SH, Goldschmidt MH, McManus PM. A comparative review of melanocytic neoplasms. Vet Pathol 2002; 39: 651-78. 60. Sulaimon SS, Kitchell BE. The basic biology of malignant melanoma: molecular mechanisms of disease progression and comparative aspects. J Vet Intern Med 2003; 17: 760-72. 61. Ohashi E, Inoue K, Kagechika H, et al. Effect of natural and synthetic retinoids on the proliferation and differentiation of three canine melanoma cell lines. J Vet Med Sci 2002; 64: 169-72. 62. Goldschmidt MH. Benign and malignant melanocytic neoplasms of domestic animals. Am J Dermatopathol 1985; 7 Suppl: 203-12. 63. Choi C, Kusewitt DF. Comparison of tyrosinase-related protein-2, S-100, and Melan A immunoreactivity in canine amelanotic melanomas. Vet Pathol 2003; 40: 713-8. 64. Catchpole B, Gould SM, Kellett-Gregory LM, Dobson JM. Development of a multiple-marker polymerase chain reaction assay for detection of metastatic melanoma in lymph node aspirates of dogs. Am J Vet Res 2003; 64: 544-9. 65. Bolon B, Calderwood Mays MB, Hall BJ. Characteristics of canine melanomas and comparison of histology and DNA ploidy to their biologic behavior. Vet Pathol 1990; 27: 96-102. 66. Freeman KP, Hahn KA, Harris FD, King GK. Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987-1997). J Vet Intern Med 2003; 17: 96-101. 67. O'Day S, Boasberg P. Management of metastatic melanoma 2005. Surg Oncol Clin N Am 2006; 15: 419-37. 68. Rassnick KM, Ruslander DM, Cotter SM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc 2001; 218: 1444-8. 69. von Euler H, Sadeghi A, Carlsson B, et al. Efficient adenovector CD40 ligand immunotherapy of canine malignant melanoma. J Immunother 2008; 31: 377-84. 70. Alexander AN, Huelsmeyer MK, Mitzey A, et al. Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother 2006; 55: 433-42. 71. Finocchiaro LM, Fiszman GL, Karara AL, Glikin GC. Suicide gene and cytokines combined nonviral gene therapy for spontaneous canine melanoma. Cancer Gene Ther 2008; 15: 165-72. 72. Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 2003; 170: 3488-94. 73. Essner R, Kojima M. Dendritic cell function in sentinel nodes. Oncology (Williston Park) 2002; 16: 27-31. 74. Li CD, Zhang WY, Yuan CL, Han LY. [Effects of ovarian carcinoma cells on the maturation and function of human dendritic cells]. Zhonghua Yi Xue Za Zhi 2009; 89: 630-4. 75. DeRosa DC, Ryan PJ, Okragly A, Witcher DR, Benschop RJ. Tumor-derived death receptor 6 modulates dendritic cell development. Cancer Immunol Immunother 2008; 57: 777-87. 76. Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q. Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 2006; 107: 2432-9. 77. Avigan DE, Vasir B, George DJ, et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007; 30: 749-61. 78. Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res 2004; 10: 4699-708. 79. Yasuda T, Kamigaki T, Nakamura T, et al. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells. Oncol Rep 2006; 16: 1317-24. 80. Zhou J, Xia JC, Wang H, et al. [Antitumor response induced by vaccine of autologous dendritic/tumor fusion cells against renal cell]. Zhonghua Zhong Liu Za Zhi 2007; 29: 411-4. 81. Ahmadzadeh M, Felipe-Silva A, Heemskerk B, et al. FOXP3 expression accurately defines the population of intratumoral regulatory T cells that selectively accumulate in metastatic melanoma lesions. Blood 2008; 112: 4953-60. 82. Pai CC, Kuo TF, Mao SJ, Chuang TF, Lin CS, Chu RM. Immunopathogenic behaviors of canine transmissible venereal tumor in dogs following an immunotherapy using dendritic/tumor cell hybrid. Vet Immunol Immunopathol; 139: 187-99. 83. Gu AD, Xie YB, Mo HY, et al. Antibodies against Epstein-Barr virus gp78 antigen: a novel marker for serological diagnosis of nasopharyngeal carcinoma detected by xMAP technology. The Journal of general virology 2008; 89: 1152-8. 84. Vernon MR, Maheshwari M, Schultz CJ, et al. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys 2008; 70: 678-84. 85. Ong SC, Schoder H, Lee NY, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med 2008; 49: 532-40. 86. Ino S, Shimada T, Kanagawa M, et al. [Development of 18F-FDG ([F-18]-2-fluoro-2-deoxy-D-glucose) injection for imaging of tumor reflecting glucose metabolism--results of preclinical studies]. Kaku igaku 1999; 36: 467-76. 87. Nishiyama Y, Yamamoto Y, Kanenishi K, et al. Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET. Eur J Nucl Med Mol Imaging 2008; 35: 287-95. 88. Mullerad M, Eisenberg DP, Akhurst TJ, et al. Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus. Mol Imaging Biol 2006; 8: 30-5. 89. Altamirano J, Esparza JR, de la Garza Salazar J, et al. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET. Arch Med Res 2008; 39: 69-77. 90. Ballegeer EA, Forrest LJ, Jeraj R, Mackie TR, Nickles RJ. PET/CT following intensity-modulated radiation therapy for primary lung tumor in a dog. Vet Radiol Ultrasound 2006; 47: 228-33. 91. Nakamoto Y, Chin BB, Kraitchman DL, Lawler LP, Marshall LT, Wahl RL. Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. Radiology 2003; 227: 817-24. 92. Cohen D. Detection of humoral antibody to the transmissible venereal tumour of the dog. Int J Cancer 1972; 10: 207-12. 93. Cohen D. The transmissible venereal tumor of the dog--a naturally occurring allograft? A review. Isr J Med Sci 1978; 14: 14-9. 94. Liao KW, Hung SW, Hsiao YW, Bennett M, Chu RM. Canine transmissible venereal tumor cell depletion of B lymphocytes: molecule(s) specifically toxic for B cells. Vet Immunol Immunopathol 2003; 92: 149-62. 95. Hess A, Cunningham B, Taylor Bennett B, Epstein R. In vitro correlates of the in vivo course of the canine transmissible venereal tumor studied by mixed lymphocyte-tumor cultures. Transplant Proc 1975; 7: 507-11. 96. Li S, Zhang X, Xia X. Regression of tumor growth and induction of long-term antitumor memory by interleukin 12 electro-gene therapy. J Natl Cancer Inst 2002; 94: 762-8. 97. Lee SC, Wu CJ, Wu PY, Huang YL, Wu CW, Tao MH. Inhibition of established subcutaneous and metastatic murine tumors by intramuscular electroporation of the interleukin-12 gene. J Biomed Sci 2003; 10: 73-86. 98. Li S. IL-12-Based therapy of malignancies. Drugs Today (Barc) 2001; 37: 629-37. 99. Pignata C, Sanghera JS, Cossette L, Pelech SL, Ritz J. Interleukin-12 induces tyrosine phosphorylation and activation of 44-kD mitogen-activated protein kinase in human T cells. Blood 1994; 83: 184-90. 100. Zhang C, Zhang J, Niu J, Zhou Z, Tian Z. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. Hum Immunol 2008; 69: 490-500. 101. Del Vecchio M, Bajetta E, Canova S, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13: 4677-85. 102. Airoldi I, Di Carlo E, Cocco C, et al. Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci U S A 2007; 104: 3996-4001. 103. Maruyama K, Takigawa Y, Akiyama Y, et al. Structure and characterization of hamster IL-12 p35 and p40. Mol Immunol 2003; 40: 319-26. 104. Maruo S, Oh-hora M, Ahn HJ, et al. B cells regulate CD40 ligand-induced IL-12 production in antigen-presenting cells (APC) during T cell/APC interactions. J Immunol 1997; 158: 120-6. 105. Chuang TF, Lee SC, Liao KW, et al. Electroporation-mediated IL-12 gene therapy in a transplantable canine cancer model. Int J Cancer 2009; 125: 698-707. 106. Brunelli M, Manfrin E, Martignoni G, et al. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am J Clin Pathol 2008; 129: 907-11. 107. Liu CC, Wang YS, Lin CY, et al. Transient downregulation of monocyte-derived dendritic-cell differentiation, function, and survival during tumoral progression and regression in an in vivo canine model of transmissible venereal tumor. Cancer Immunol Immunother 2008; 57: 479-91. 108. Misdorp W, Else RW, Hellme´n E, Lipscomb TP. Histological Classification of Mammary Tumors of the Dog and the Cat, 2nd series, Vol. VII, Armed Forces Institute of Pathology, American Registry of Pathology, Washington, DC and the World Health Organization Collaborating Center for Worldwide Reference on Comparative Oncology. 1999: pp. 1-59. 109. Hsiao YW, Liao KW, Chung TF, Liu CH, Hsu CD, Chu RM. Interactions of host IL-6 and IFN-gamma and cancer-derived TGF-beta1 on MHC molecule expression during tumor spontaneous regression. Cancer Immunol Immunother 2008; 57: 1091-104. 110. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3: 558-61. 111. Chou PC, Chuang TF, Jan TR, et al. Effects of immunotherapy of IL-6 and IL-15 plasmids on transmissible venereal tumor in beagles. Vet Immunol Immunopathol 2009; 130: 25-34. 112. Hsiao Y-W, Liao K-W, Chung T-F, Liu C-H, Hsu C-D, Chu R-M. Interactions of host IL-6 and IFN-γ and cancer-derived TGF-β1 on MHC molecule expression during tumor spontaneous regression Cancer Immuno immnopathol 2008; 57: 1091-104. 113. Biller BJ, Elmslie RE, Burnett RC, Avery AC, Dow SW. Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Vet Immunol Immunopathol 2007; 116: 69-78. 114. Tuettenberg A, Schmitt E, Knop J, Jonuleit H. Dendritic cell-based immunotherapy of malignant melanoma: success and limitations. J Dtsch Dermatol Ges 2007; 5: 190-6. 115. Hsiao YW, Liao KW, Hung SW, Chu RM. Effect of tumor infiltrating lymphocytes on the expression of MHC molecules in canine transmissible venereal tumor cells. Vet Immunol Immunopathol 2002; 87: 19-27. 116. Yano K, Ide K, Momoi Y, Yamazoe K, Kudo T. Enhancement of reactive oxygen species production from canine blood leukocytes by human recombinant interleukin-12. Vet Immunol Immunopathol 2003; 93: 1-8. 117. Phillips BS, Padilla ML, Dickerson EB, Lindstrom MJ, Helfand SC. Immunostimulatory effects of human recombinant interleukin-12 on peripheral blood mononuclear cells from normal dogs. Vet Immunol Immunopathol 1999; 70: 189-201. 118. Liu CC, Wang YS, Lin CY, et al. Transient downregulation of monocyte-derived dendritic-cell differentiation, function, and survival during tumoral progression and regression in an in vivo canine model of transmissible venereal tumor. Cancer Immunol Immunother 2007. 119. Kurzman ID, Gilbertson SR. Prognostic factors in canine mammary tumors. Semin Vet Med Surg (Small Anim) 1986; 1: 25-32. 120. Xia D, Moyana T, Xiang J. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors. Cell Res 2006; 16: 241-59. 121. Gao JQ, Kanagawa N, Motomura Y, et al. Cotransduction of CCL27 gene can improve the efficacy and safety of IL-12 gene therapy for cancer. Gene Ther 2007. 122. Hansen K, Khanna C. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development. European journal of cancer 2004; 40: 858-80. 123. Kirkness EF, Bafna V, Halpern AL, et al. The dog genome: survey sequencing and comparative analysis. Science 2003; 301: 1898-903. 124. Spugnini EP, Dragonetti E, Vincenzi B, Onori N, Citro G, Baldi A. Pulse-mediated chemotherapy enhances local control and survival in a spontaneous canine model of primary mucosal melanoma. Melanoma research 2006; 16: 23-7. 125. Danish National Board of Health: Cancer incidence in Denmark. [in Danish] 2008; 12. 126. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 2000; 18: 781-92. 127. Hayes HM, Jr., Hoover R, Tarone RE. Bladder cancer in pet dogs: a sentinel for environmental cancer? Am J Epidemiol 1981; 114: 229-33. 128. Oyamada T, Tanaka H, Park CH, Ueki H, Komiya T, Arai S. Pathology of canine oral malignant melanoma with cartilage and/or osteoid formation. J Vet Med Sci 2007; 69: 1155-61. 129. Meleti M, Leemans CR, Mooi WJ, Vescovi P, van der Waal I. Oral malignant melanoma: a review of the literature. Oral Oncol 2007; 43: 116-21. 130. Meleti M, Leemans CR, de Bree R, Vescovi P, Sesenna E, van der Waal I. Head and neck mucosal melanoma: experience with 42 patients, with emphasis on the role of postoperative radiotherapy. Head Neck 2008; 30: 1543-51. 131. MacEwen EG. Spontaneous tumors in dogs and cats: models for the study of cancer biology and treatment. Cancer Metastasis Rev 1990; 9: 125-36. 132. Albert RE, Benjamin SA, Shukla R. Life span and cancer mortality in the beagle dog and humans. Mech Ageing Dev 1994; 74: 149-59. 133. Cotman CW, Head E. The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J Alzheimers Dis 2008; 15: 685-707. 134. Reif JS, Bruns C, Lower KS. Cancer of the nasal cavity and paranasal sinuses and exposure to environmental tobacco smoke in pet dogs. Am J Epidemiol 1998; 147: 488-92. 135. Knapp DW, Waters DJ. Naturally occurring cancer in pet dogs: important models for developing improved cancer therapy for humans. Mol Med Today 1997; 3: 8-11. 136. Dow S, Elmslie R, Kurzman I, MacEwen G, Pericle F, Liggitt D. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Human gene therapy 2005; 16: 937-46. 137. Bianco SR, Sun J, Fosmire SP, et al. Enhancing antimelanoma immune responses through apoptosis. Cancer gene therapy 2003; 10: 726-36. 138. Dow SW, Elmslie RE, Willson AP, Roche L, Gorman C, Potter TA. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. The Journal of clinical investigation 1998; 101: 2406-14. 139. Finocchiaro LM, Glikin GC. Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma. Gene Ther 2008; 15: 267-76. 140. Bird RC, Deinnocentes P, Lenz S, Thacker EE, Curiel DT, Smith BF. An allogeneic hybrid-cell fusion vaccine against canine mammary cancer. Vet Immunol Immunopathol 2008; 123: 289-304. 141. Bird RC, Deinnocentes P, Church Bird AE, van Ginkel FW, Lindquist J, Smith BF. An autologous dendritic cell canine mammary tumor hybrid-cell fusion vaccine. Cancer Immunol Immunother 2011; 60: 87-97. 142. Jacob J, Radkevich O, Forni G, et al. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol 2006; 240: 96-106. 143. Foy TM, Bannink J, Sutherland RA, et al. Vaccination with Her-2/neu DNA or protein subunits protects against growth of a Her-2/neu-expressing murine tumor. Vaccine 2001; 19: 2598-606. 144. Lachman LB, Rao XM, Kremer RH, Ozpolat B, Kiriakova G, Price JE. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Ther 2001; 8: 259-68. 145. Amici A, Smorlesi A, Noce G, et al. DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther 2000; 7: 703-6. 146. Smorlesi A, Papalini F, Pierpaoli S, Provinciali M. HER2/neu DNA vaccination for breast tumors. Methods Mol Biol 2008; 423: 473-85. 147. Pupa SM, Iezzi M, Di Carlo E, et al. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 2005; 65: 1071-8. 148. Chang SY, Lee KC, Ko SY, Ko HJ, Kang CY. Enhanced efficacy of DNA vaccination against Her-2/neu tumor antigen by genetic adjuvants. Int J Cancer 2004; 111: 86-95. 149. Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 2004; 6: R275-83. 150. Ko HJ, Kim YJ, Kim YS, et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 2007; 67: 7477-86. 151. Yo YT, Hsu KF, Shieh GS, et al. Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine. Cancer Gene Ther 2007; 14: 904-17. 152. Quaglino E, Iezzi M, Mastini C, et al. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 2004; 64: 2858-64. 153. Peruzzi D, Mesiti G, Ciliberto G, La Monica N, Aurisicchio L. Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Vaccine 2010; 28: 1201-8. 154. Ko HJ, Kim YJ, Kim YS, et al. Immunogenicity and safety profiles of genetic vaccines against human Her-2/neu in cynomolgus monkeys. Gene Ther 2008; 15: 1351-60. 155. Goubier A, Fuhrmann L, Forest L, et al. Superiority of needle-free transdermal plasmid delivery for the induction of antigen-specific IFNgamma T cell responses in the dog. Vaccine 2008; 26: 2186-90. 156. Buchan S, Gronevik E, Mathiesen I, King CA, Stevenson FK, Rice J. Electroporation as a 'prime/boost' strategy for naked DNA vaccination against a tumor antigen. J Immunol 2005; 174: 6292-8. 157. Supriatno, Yuletnawati SE, Widiasto A. Effect of intratumoral injection of mutant type p27Kip1 followed by in vivo electroporation on radiotherapy-resistant human oral tongue cancer xenografts. Mol Med Report; 4: 41-6. 158. Widera G, Austin M, Rabussay D, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164: 4635-40. 159. Trollet C, Bloquel C, Scherman D, Bigey P. Electrotransfer into skeletal muscle for protein expression. Curr Gene Ther 2006; 6: 561-78. 160. Low L, Mander A, McCann K, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009; 20: 1269-78. 161. Luckay A, Sidhu MK, Kjeken R, et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007; 81: 5257-69. 162. Tsang C, Babiuk S, van Drunen Littel-van den Hurk S, Babiuk LA, Griebel P. A single DNA immunization in combination with electroporation prolongs the primary immune response and maintains immune memory for six months. Vaccine 2007; 25: 5485-94. 163. Orlandi F, Venanzi FM, Concetti A, et al. Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine. Clin Cancer Res 2007; 13: 6195-203. 164. MacEwen EG, Harvey HJ, Patnaik AK, et al. Evaluation of effects of levamisole and surgery on canine mammary cancer. J Biol Response Mod 1985; 4: 418-26. 165. Poirier VJ, Hershey AE, Burgess KE, et al. Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. J Vet Intern Med 2004; 18: 219-22. 166. Simon D, Schoenrock D, Baumgartner W, Nolte I. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. J Vet Intern Med 2006; 20: 1184-90. 167. Bissery MC, Nohynek G, Sanderink GJ, Lavelle F. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs 1995; 6: 339-55, 63-8. 168. Hellmen E, Bergstrom R, Holmberg L, Spangberg IB, Hansson K, Lindgren A. Prognostic factors in canine mammary tumors: a multivariate study of 202 consecutive cases. Vet Pathol 1993; 30: 20-7. 169. Perez Alenza MD, Tabanera E, Pena L. Inflammatory mammary carcinoma in dogs: 33 cases (1995-1999). J Am Vet Med Assoc 2001; 219: 1110-4. 170. Yamagami T, Kobayashi T, Takahashi K, Sugiyama M. Prognosis for canine malignant mammary tumors based on TNM and histologic classification. J Vet Med Sci 1996; 58: 1079-83. 171. Bostock DE. Canine and feline mammary neoplasms. Br Vet J 1986; 142: 506-15. 172. Proulx DR, Ruslander DM, Dodge RK, et al. A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound 2003; 44: 352-9. 173. Wolchok JD, Yuan J, Houghton AN, et al. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 2007; 15: 2044-50. 174. Tamura K, Yamada M, Isotani M, et al. Induction of dendritic cell-mediated immune responses against canine malignant melanoma cells. Vet J 2008; 175: 126-9. 175. Lim DS, Kim JH, Lee DS, Yoon CH, Bae YS. DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradic | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/42887 | - |
dc.description.abstract | 癌症是引起動物死亡的主要原因之一。在犬癌症中,乳腺腫瘤是母犬最常見的腫瘤,占所有腫瘤發生率的50%,在組織學診斷中,發現為惡性乳腺腫瘤的機率為50%。口腔惡性腫瘤中,黑色素瘤是最常見的腫瘤,是一個極端侵略性的腫瘤,發生率為20%-50%。手術切除是乳腺腫瘤和黑色素瘤最主要的治療方式,但是預後不佳,容易復發或轉移。其他輔助治療,例如化療、放射線治療或賀爾蒙治療都無法有效增進手術的效果,因此,在本篇論文中,我們針對惡性乳腺腫瘤和黑色素瘤發展新的治療策略,期望改善腫瘤病犬的預後與生活品質。
首先,在惡性乳腺腫瘤治療研究上,依據最近的標把治療和免疫治療,我們設計了異種Her2 DNA疫苗(xenogeneic Her2 DNA vaccine)輔助手術治療犬惡性乳腺腫瘤,總計有29隻患有惡性乳腺病犬納入研究中,分為兩組:一組為控制組(只有進行手術移除),一組為Her2組(手術與疫苗合併治療)。此DNA疫苗給予的方式為2次皮內注射加上1次肌肉電衝, 在臨床上,異種DNA疫苗可以克服Her2自我抗原在動物體內的免疫耐受性,刺激特異性ELIspot IFN-γ反應。結果顯示,DNA疫苗輔助手術可以抑制腫瘤生長和遠端轉移,延遲手術後原位復發。在Her2組,此疫苗明顯延長病犬的存活時間,平均為678天(212-779天),控制組為249天(142-573天),除此之外,此DNA疫苗對於病犬無任何副作用,在犬惡性乳腺腫瘤,此異體DNA疫苗合併手術切除治療惡性乳腺腫瘤,為一個具有高度潛力的治療方式。 其次,因為在惡性黑色素瘤治療研究上,還未發現以骨髓來源樹狀細胞/腫瘤融合疫苗治療犬口腔黑色素瘤的文獻,於是我們進一步評估樹狀細胞/黑色素瘤融合疫苗在犬口腔黑色素瘤的治療效果。我們也比較單獨治療或者手術與疫苗合併治療在臨床上的效果。一共有31隻犬被納入此研究中,此31隻犬全為口腔黑色素瘤第三期,被分成三組:一組為控制組(只有進行手術移除,SR),一組為單獨進行疫苗治療(VO),一組為手術與疫苗合併治療組(CT)。在合併治療組(CT),疫苗可以明顯延長犬存活時間為259天(90-350天),在疫苗單獨治療組(VO)為124天(43-231天) 和單獨手術組(SR)為82天(50-140天)。更進一步,合併治療可以顯著降低轉移率,從單獨手術組的56%降低至合併治療組的30%,且延遲原位復發。更可以增強腫瘤特異性T細胞毒殺能力,在合併治療組為30.4% ± 14.6%,在單獨治療組為20.1% ± 9.5%,治療前則為5.7% ± 2.7%。合併治療組中,犬周圍血液中的Treg細胞明顯的下降。此融合細胞疫苗對病畜是安全的。這些研究結果指出樹狀細胞/腫瘤融合疫苗與手術合併使用對於口腔黑色素瘤是有效的治療策略,可以改善病畜的生活品質。此合併治療策略可以考慮用於臨床口腔黑色素瘤的治療或其他哺乳動物的癌症治療。 最後,我們發展新的技術去偵測免疫治療的反應,使用影像學診斷與傳統的解剖學變化相比,可以更快速偵測到免疫反應,也比組織學的方式更無侵入性。在過去的癌症免疫學治療中,PET/CT已經使用在小鼠模式中去評估抗腫瘤反應,但是在較大型動物模式(犬模式)中很少有研究去監控腫瘤免疫治療的效果。犬傳染性花柳性腫瘤是唯一可以在犬身上人工接種的腫瘤,是最佳的犬腫瘤模式,我們之前已經發表過使用腫瘤內電衝IL-12基因,會導致CTVT腫瘤消退且明顯吸引大量腫瘤浸潤淋巴球,於是在此研究中我們更進一步使用FDG-PET去偵測此免疫治療的反應,我們可以發現CTVT腫瘤的代謝是可以被FDG-PET偵測且腫瘤變化可以在早期就被發現。我們測試了不同的時間,發現在FDG注射後的60分鐘,FDG的吸收率達到穩定的狀態,此外,IL-12免疫治療將導致每單位體積較高的FDG吸收率,此趨勢可以在CTVT接種後第19天被偵測到,而給予病犬IL-12與FDG並無任何毒性產生,FDG-PET/CT可以早期偵測免疫治療對腫瘤造成的真實變化,因此我們可以推測此免疫治療是否為成功的治療,隨時操控治療策略,將可以提高治療的成功率。 犬癌症的研究可以在小鼠臨床前研究與人類臨床試驗間扮演一個重要橋樑,促進獸醫與人類癌症共同研究,這樣模式的研究將導致犬癌症與人類癌症的治療成果蓬勃發展。 | zh_TW |
dc.description.abstract | Cancer is the most common disease-associated cause of death or euthanasia in older canines. Among canine cancers, mammary gland tumor (MGT) is the most common tumor in female canines accounting for near 50% of all tumors and around 50% of those MGT is malignant. The oral melanoma accounted for 20% to 50% of oral malignancies and has been routinely considered an extremely aggressive tumor. So far, surgical excision is the most widely accepted treatment for MGT and oral melanoma, however, it offers poorly on long term prognostic or preventing metastasis in malignant cases. Other adjunctive therapies, such as chemotherapy, radiation or hormone therapy, cannot effectively promote the therapeutic effect of surgical removal. In this thesis, we looked for new approaches to therapy malignant MGT and oral melanoma and to achieve a good quality of life in canine patients.
First, according to recent achievement in targeted therapy and immunotherapy, we applied a recombinant rat Her2 xenogeneic DNA vaccine, pING-rHer2, to treat canine malignant MGTs following surgical removal of the tumor masses. Twenty-nine canines with MGT were enrolled in this program and were divided into two groups, control (surgical removal only) and Her2 (combined treatment, surgery plus vaccination). The DNA vaccine was delivered by two transdermal injections followed by an intramuscular electroporation. The antigen-specific ELIspot IFN-γ response elicited by pIGN-rHer2 DNA vaccinations was a clear demonstration that this vaccine was able to overcome tolerance to the Her2 self antigen under clinically relevant conditions. Furthermore, the results demonstrated that surgery combined with pING-rHer2 DNA vaccination significantly restrained the tumor growth and distant mestastasis, and substantially postponed post-surgical recurrence in canine spontaneous malignant MGT. The vaccine significantly prolonged the patients overall survival time in the Her2 group. In addition, there was no detectable side effect. In conclusion, this xenogeneic DNA vaccine should be further considered as a potential immunotherapy of canine malignant MGT. Second, because the use of an allogeneic bone marrow-derived dendritic cell (BMDC)/tumor cell fusion vaccine to treat canine oral malignant melanoma has not been documented and the efficacy of the BMDC/syngeneic melanoma cell fusion vaccine was evaluated in canine oral melanoma patients. We also compared the clinical benefits for patients between single treatments and a combination protocol of surgery/fusion vaccine. Thirty-one canines with stage III oral melanoma were enrolled in this program and were divided into three groups, SR (surgical removal only), VO (vaccination only) and CT (combined treatment, surgery plus vaccination). The vaccine significantly improved the overall survival time in the CT group (259 days; 90–350 days) in comparison with the VO (124 days; 43–231days) and SR groups (82 days; 50–140 days). Moreover, the CT protocol dramatically decreased the metastatic rate and delayed in situ recurrence; it also stimulated potent tumor cell-specific cytotoxic T lymphocytes (CTL). In addition, the population of Treg cells in peripheral blood decreased significantly in the CT canines in comparison with the other groups. Besides, there was no clinically-detectable toxicity. These results indicate that surgical removal combined with the allogeneic BMDC/syngeneic tumor cell fusion vaccine was the effective treatment protocol for late-stage canine oral melanoma and resulted in an improvement in quality of life. It is suggested that this combined protocol can be considered one of the treatments of choice for canine oral melanoma and has the potential to be used in other mammals. Furthermore, we have developed new image technique to indicate immunotherapy response sooner than anatomic changes depicted by traditional modalities, and less invasively than histological sampling. Regarding immunotherapy of cancer, PET/CT has been used in mice models to evaluate antitumor response. There are few researches in monitoring the efficacy of cancer immunotherapy in larger animal models such as canines using PET/CT. Canine transmissible venereal tumor (CTVT) can be experimentally transplanted to allogeneic canines. CTVT is an ideal model for cancer study. Previously, we have publisded that intratumoral electroporation of pIL-12 resulted in successful tumor regression and attracted significantly more lymphocytes infiltrating to the tumors in the canine CTVT model. CTVT metabolism can be measured by serial FDG-PET scansand the change of tumor in the early phase can be detected. At 60 min after FDG delivery, there was a stable trend of FDG uptake ratio in CTVT. The pIL-12 immunotherapy resulted inhigher FDG uptake ratios per volume of CTVT, which can be detected as early as 19 days after CTVT inoculation. Delivery of pIL-12 and FDG did not result in any detectable toxicity in the canines. The FDG PET/CT early detect the tumor growth pattern. The ability of FDG PET/CT to measure tumor growth directly after the commencement of treatment may provide an early indicator of the success of therapy. Immediately, the strategies of treatment will be managed. The FDG PET/CT will improve the diagnosis of the efficacy and successful rate of future immunotherapy clinical trials in cancer patients. Therefore, these protocols have the potential to be used in other canine cancers. Canine cancers may serve as an important bridge between preclinical studies in mouse model systems and clinical trials in humans with cancer and support the synergy of collaborations between veterinary and human cancer centers. Such collaboration will result in the development of therapy in canines cancers and has shown promising results in humans. | en |
dc.description.provenance | Made available in DSpace on 2021-06-15T01:27:37Z (GMT). No. of bitstreams: 1 ntu-100-D94629002-1.pdf: 7819697 bytes, checksum: 43b827dd51c7af5cd3e01e085bb92565 (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 口試委員會審定書..............................I
誌謝..........................................II 中文摘要......................................III Abstract......................................VI Chapter 1.....................................1 Background and Literatures review.............1 A. Canines and cancers..................1 B. Xenogeneic Her2/neu immunization for malignant mammary gland tumor...........................8 C. Allogeneic bone marrow-derived dendritic cells/syngeneic melanoma hybrids in canine oral melanoma .....................................14 D. The evaluation anticancer response to immunotherapy by 18F-Fluorodeoxyglucose PET/CT in canine model FDG-PET/CT..............................20 Chapter 2.....................................24 Xenogeneic Her2/neu immunization inhibits recurrence of spontaneous malignant mammary gland tumor and extend survival time in canines......................24 Materials and Methods.........................26 Results.......................................33 Chapter 3.....................................48 Clinical application of allogeneic bone marrow-derived dendritic cells/syngeneic melanoma hybrids as an adjuvant to surgery delays tumor recurrence in stage III canine oral melanoma......................................48 Materials and Methods.........................50 Results.......................................57 Chapter 4.....................................74 Use of 18F-Fluorodeoxyglucose PET/CT for evaluating anticancer response to immunotherapy in canine model .....................................74 Materials and methods.........................76 Results.......................................81 Chapter 5.....................................94 Discussion....................................94 A. Naturally occurring cancer in canines as important models for developing improved cancer therapy for humans........................................96 B. Xenogeneic Her2/neu immunization for malignant mammary gland tumor...........................99 C. Allogeneic bone marrow-derived dendritic cells/syngeneic melanoma hybrids in canine oral melanoma .....................................106 D. The evaluation anticancer response to immunotherapy by 18F-Fluorodeoxyglucose PET/CT for in canine model FDG-PET/CT........................112 Chapter 6......................................119 References.....................................119 | |
dc.language.iso | en | |
dc.title | 犬癌症之免疫治療與影像診斷 | zh_TW |
dc.title | Immunotherapy and imaging diagnosis of canine cancers | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-2 | |
dc.description.degree | 博士 | |
dc.contributor.advisor-orcid | ,朱瑞民(redman@ntu.edu.tw) | |
dc.contributor.oralexamcommittee | 曾凱元(Kai-Yuan Tzen),林中天(Chung-Tien Lin),詹東榮(Tong-Rong Jan) | |
dc.subject.keyword | 犬,乳腺腫瘤,黑色素瘤,免疫治療,融合疫苗,正子照影, | zh_TW |
dc.subject.keyword | Canine,Mammary gland tumor,Oral melanoma,Immunotherapy,Her2 DNA vaccine,Fusion vaccine,FDG PET/CT, | en |
dc.relation.page | 133 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2011-08-16 | |
dc.contributor.author-college | 獸醫專業學院 | zh_TW |
dc.contributor.author-dept | 獸醫學研究所 | zh_TW |
顯示於系所單位: | 獸醫學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 7.64 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。